Cargando…
Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study
BACKGROUND: Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563646/ https://www.ncbi.nlm.nih.gov/pubmed/23390507 http://dx.doi.org/10.1371/journal.pone.0054941 |
_version_ | 1782258233112526848 |
---|---|
author | Xi, Jiafei Zhu, Honghu Liu, Daqing Nan, Xue Zheng, Wen Liu, Kaiyan Shi, Wei Chen, Lin Lv, Yang Yan, Fang Li, Yanhua Xie, Xiaoyan Wang, Yunfang Yue, Wen Xu, Xin Wei, Xiaofei Zhu, Jun Huang, Xiaojun Pei, Xuetao |
author_facet | Xi, Jiafei Zhu, Honghu Liu, Daqing Nan, Xue Zheng, Wen Liu, Kaiyan Shi, Wei Chen, Lin Lv, Yang Yan, Fang Li, Yanhua Xie, Xiaoyan Wang, Yunfang Yue, Wen Xu, Xin Wei, Xiaofei Zhu, Jun Huang, Xiaojun Pei, Xuetao |
author_sort | Xi, Jiafei |
collection | PubMed |
description | BACKGROUND: Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the present study, our objective was to determine the safety and feasibility of ex vivo generated MPs in patients. METHODS AND FINDINGS: MPs were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. We investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancyes. The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. No adverse effects were observed in patients who received ex vivo-generated cells at concentrations of up to a median value of 5.45×10(6)cells/kg of body weight. With one year follow-up, acute and chronic GVHD had not been observed among patients who received MPs infusion, even without ABO blood group and HLA typing matching. CONCLUSIONS: These initial results in patients are very encouraging. They suggest that infusion of cord blood-derived MPs appears safe and feasible for treatment of thrombocytopenia. TRIAL REGISTRATION: www.chictr.org ChiCTR-TCH-09000333. |
format | Online Article Text |
id | pubmed-3563646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35636462013-02-06 Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study Xi, Jiafei Zhu, Honghu Liu, Daqing Nan, Xue Zheng, Wen Liu, Kaiyan Shi, Wei Chen, Lin Lv, Yang Yan, Fang Li, Yanhua Xie, Xiaoyan Wang, Yunfang Yue, Wen Xu, Xin Wei, Xiaofei Zhu, Jun Huang, Xiaojun Pei, Xuetao PLoS One Research Article BACKGROUND: Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the present study, our objective was to determine the safety and feasibility of ex vivo generated MPs in patients. METHODS AND FINDINGS: MPs were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. We investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancyes. The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. No adverse effects were observed in patients who received ex vivo-generated cells at concentrations of up to a median value of 5.45×10(6)cells/kg of body weight. With one year follow-up, acute and chronic GVHD had not been observed among patients who received MPs infusion, even without ABO blood group and HLA typing matching. CONCLUSIONS: These initial results in patients are very encouraging. They suggest that infusion of cord blood-derived MPs appears safe and feasible for treatment of thrombocytopenia. TRIAL REGISTRATION: www.chictr.org ChiCTR-TCH-09000333. Public Library of Science 2013-02-04 /pmc/articles/PMC3563646/ /pubmed/23390507 http://dx.doi.org/10.1371/journal.pone.0054941 Text en © 2013 Xi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Xi, Jiafei Zhu, Honghu Liu, Daqing Nan, Xue Zheng, Wen Liu, Kaiyan Shi, Wei Chen, Lin Lv, Yang Yan, Fang Li, Yanhua Xie, Xiaoyan Wang, Yunfang Yue, Wen Xu, Xin Wei, Xiaofei Zhu, Jun Huang, Xiaojun Pei, Xuetao Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title | Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title_full | Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title_fullStr | Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title_full_unstemmed | Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title_short | Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study |
title_sort | infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563646/ https://www.ncbi.nlm.nih.gov/pubmed/23390507 http://dx.doi.org/10.1371/journal.pone.0054941 |
work_keys_str_mv | AT xijiafei infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT zhuhonghu infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT liudaqing infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT nanxue infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT zhengwen infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT liukaiyan infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT shiwei infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT chenlin infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT lvyang infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT yanfang infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT liyanhua infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT xiexiaoyan infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT wangyunfang infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT yuewen infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT xuxin infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT weixiaofei infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT zhujun infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT huangxiaojun infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study AT peixuetao infusionofmegakaryocyticprogenitorproductsgeneratedfromcordbloodhematopoieticstemprogenitorcellsresultsofthephase1study |